Save Product
Product Details
Synonyms
FCGR3A, CD16A, FCG3, FCGR3, IGFR3
Source
Human CD16a (F176), His Tag (CDA-H5220) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # P08637-1).
Predicted N-terminus: Gly 17
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 23.7 kDa. The protein migrates as 39-51 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.1 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human CD16a (F176), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human CD16a (F176), His Tag (Cat. No. CDA-H5220) is more than 90% and the molecular weight of this protein is around 30-45 kDa verified by SEC-MALS.
Report
Bioactivity-SPR
Human CD16a (F176), His Tag (Cat. No. CDA-H5220) captured on CM5 chip via anti-His antibody can bind Rituximab biosimilar (Cat. No. CD0-M36) with an affinity constant of 1.18 µM as determined in a SPR assay (Biacore 8K) (QC tested).
Protocol
Rituximab biosimilar (Cat. No. CD0-M36) captured on Protein A Chip can bind Human CD16a (F176), His Tag (Cat. No. CDA-H5220) with an affinity constant of 1.98 µM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
A***n2025-02-12
LikesAcro's Fc gamma receptor proteins are my top choice for Octet binding assays. They consistently deliver reliable results, crucial for accurate research. Their product quality is outstanding, ensuring reproducible experiments. Acro's technical service is exceptional, with a responsive and knowledgeable support team. Their comprehensive range of well-characterized Fc receptor proteins, high purity, and bioactivity have made them my exclusive supplier. The attention to quality control ensures excellent batch-to-batch consistency.- 1***62019-10-16 LikesWe purchased several Fc receptor proteins. Our purpose is to test the binding affinity between antibodies and Fc receptors using Fortebio. Compared with products from other vendors, Acro's products have a higher purity and better bioactivity. Besides, their delivery is really fast. Looking forward to buying more products from ACRO in the future!
Background
CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibodydependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.
Recent Advances
Drug Development Progress- English Name：
Low affinity immunoglobulin gamma Fc region receptor III-A
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
14 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
